AZ/MedImmune's FluMist gets big boost with new indication

Share this article:
MedImmune announced that the FDA has approved the use of its FluMist in children 2-5 years old, an indication that significantly expands the market for the nasal vaccine.

The company, which AstraZeneca acquired for $15.6 billion in June, had initially seen disappointing returns on the product, approved in 2003 for patients ages 5-49, due to its onerous storage requirements and its age restrictions – the very young and old being the most vulnerable to influenza. It brought in a meager $36.4 million last year.

However, the company won approval for a new formulation that could be stored refrigerated instead of frozen early this year, and now, with access to one of the prime markets for flu vaccines, the product's prospects are looking brighter.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.